



MATERIAL SAFETY DATA SHEET

Product Name: Morphine Sulfate Injection, USP 

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

**Manufacturer Name
And Address** Hospira, Inc.
275 North Field Drive
Lake Forest, Illinois 60045
USA

Note: Hospira, formerly the Hospital Products Division of Abbott Laboratories, was created as an independent company in May 2004.

**Emergency Telephone
Hospira, Inc.** CHEMTREC: 800 424-9300
224 212-2055

Product Name Morphine Sulfate Injection, USP

Synonyms None

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name Morphine Sulfate
Chemical Formula $C_{34}H_{40}N_2O_{10}S$

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Morphine Sulfate	0.05 - 5	64-31-3	QC8750000
Water	99	7732-18-5	ZC0110000

3. HAZARD INFORMATION

Emergency Overview In clinical use, this material is used to treat pain. Possible target organs include the central nervous system, eyes, respiratory system, gastrointestinal tract, and cardiovascular system.

**Occupational Exposure
Potential** Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms No signs or symptoms from occupational exposure are known. Clinical data suggest the following: constipation, nausea, vomiting, lightheadedness, dizziness, sedation, euphoria, sweating, edema, chills, tremor, flushing, altered blood pressure, palpitation, faintness, dry mouth, skin discoloration, hallucinations, blurred vision, urine retention, breathing difficulty, rash.

**Medical Conditions
Aggravated by Exposure** Hypersensitivity to the material and/or similar materials. Pre-existing ailments in the following organs: eyes, central nervous system, respiratory system, gastrointestinal system, female reproductive system.

Product Name: Morphine Sulfate Injection, USP

4. FIRST AID MEASURES

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability: Non-flammable

Fire & Explosion Hazard: None

Extinguishing Media: Use extinguishing media appropriate for primary cause of fire.

Special Fire Fighting Procedures No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal Absorb with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling Protect from light by retaining in carton until contents have been used.

Storage No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F).

Special Precautions Protect from freezing, light and extreme heat.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Exposure limits		
	OSHA-PEL	ACGIH-TLV	Hospira EEL
Morphine Sulfate	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: 5 mcg/m ³ STEL: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.

Product Name: Morphine Sulfate Injection, USP

Respiratory Protection Respiratory protection is not needed during normal product use.

Skin Protection If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.

Eye Protection Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.

Engineering Controls Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State Clear liquid

Odor None

Boiling Point Approximately that of water (100 °C, 212 °F).

Freezing Point Approximately that of water (0 °C, 32 °F).

Vapor Pressure Approximately that of water (17.5 mm Hg at 20 °C).

Vapor Density (Air=1) Not Applicable

Evaporation Rate Not Applicable

Bulk Density Not Determined

Specific Gravity Approximately that of water (1.0).

Solubility Aqueous solution

pH 2.5 – 6.0

10. STABILITY AND REACTIVITY

Chemical Stability Stable under standard use and storage conditions.

Incompatibilities Alkalies, tannic acid, iodic acid, potassium permanganate, borax, chlorates, ferric chloride, iodides, lead acetate, magnesia, mercury bichloride.

Hazardous Decomposition Products Toxic fumes of nitrogen oxides

Hazardous Polymerization Not Determined.

11. TOXICOLOGICAL INFORMATION:

Acute Toxicity – Oral:

Ingredient(s)	Percent	Test Type	Value	Units	Species
Morphine Sulfate	100	LD50	461-600	mg/kg	Mice, Rats

LD50 is the dosage producing 50% mortality.
Product contains between approximately 0.05-5% Morphine Sulfate.

Mutagenicity Mutagenic in micronucleus assay. Mutagenic in the one or more mutagenicity bioassays.

Target Organ Effects In clinical use target organ effects include central nervous system, eyes, respiratory system, gastrointestinal tract, cardiovascular system, female reproductive system.

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity Not Available

Product Name: Morphine Sulfate Injection, USP

13. DISPOSAL CONSIDERATIONS:

Waste Disposal	Disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal	Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

DOT Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status	Not Regulated
CERCLA Status	Not Regulated
SARA Status	Not Regulated
RCRA Status	Not Regulated
PROP 65 (Calif.)	Not Regulated

Notes: TSCA Toxic Substance Control Act
CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
SARA Superfund Amendments and Reauthorization Act
RCRA US EPA, Resource Conservation and Recovery Act
Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator	T. Straits MPH, CIH
Date Prepared	September 15, 2005

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.